Merck’s Oral Antiviral Pill ‘Molnupiravir’: could be a Covid-19 Pandemic Game-Changer

Authors

  • Jyoti Prakash Sahoo Dept. of Agricultural Biotechnology, College of Agriculture, Odisha University of Agriculture and Technology, Bhubaneswar, Odisha (751 003), India
  • Sudhanya Nath Dept. of Animal Nutrition, West Bengal University of Animal & Fishery Sciences, Kolkata, West Bengal (700 037), India
  • Kailash Chandra Samal Dept. of Agricultural Biotechnology, College of Agriculture, Odisha University of Agriculture and Technology, Bhubaneswar, Odisha (751 003), India

Keywords:

Covid-19, Game-changer, Molnupiravir, Oral drug

Abstract

Countries all across the Asia-Pacific region are galloping to place orders for the latest armament which can help in battling the deadly Coronavirus, an antiviral pill that has not yet been approved for use, termed as Molnupiravir and manufactured by US pharmaceutical company Merck. The pill is being deemed as a potential game-changer in the event of a pandemic, especially for the individuals who are unable to get vaccinated. As of now, at least eight countries or territories in the Asia-Pacific area have signed agreements or are in the process of doing so to obtain the drug. New Zealand, Australia, and South Korea are among these countries. Merck is seeking an emergency use authorization for the drug from the US Food and Drug Administration. If approved, the capsule will be the first antiviral treatment against Covid-19 that is used orally.

Downloads

Download data is not yet available.
Biotica Research Today Vol 3 Issue 10 Cover Page

Downloads

Published

2021-10-26

How to Cite

[1]
Sahoo, J.P. et al. 2021. Merck’s Oral Antiviral Pill ‘Molnupiravir’: could be a Covid-19 Pandemic Game-Changer. Biotica Research Today. 3, 10 (Oct. 2021), 912–915.

Issue

Vol. 3 No. 10 (2021): October, 2021

Section

General Article

Most read articles by the same author(s)

1 2 3 4 5 6 > >>